Ionis Pharmaceuticals, Inc.

IONS

Precision medicineBiotech & pharmaceuticals

$61.78vs prev close▲+2.04(+3.41%)

$41.7152W Range$86.74

45% from low

+3.19 (+5.64%)Past 1M

Price

ARK Trade PatternPREMIUM

1M Trades

3 buys

Concentrated buys

1M net buy

+$3.1M

≈ +52K shares

Portfolio Weight

0.23%

1M +0.06%p

Holding ETFs

1 ETFs

ARKG

Buy · Weight Up

ARK net-bought the stock and the price rose, increasing its portfolio weight.

Shares +87.8% · Market value +22.4% · Weight +0.06%p

Trade Intensity

Minor adjustment

Basis: 0 sells · 3 buys in 1M

Trade Log3-day BUY streak

Date	Action	ETF	Shares	Close	Est. total
26.08.19	BUY	ARKG	18,499	$60.80	$1.1M
26.08.18	BUY	ARKG	26,246	$59.62	$1.6M
26.08.17	BUY	ARKG	6,839	$58.63	$401.0K
26.07.14	BUY	ARKG	49,003	$54.93	$2.7M
26.07.13	BUY	ARKG	66,277	$56.75	$3.8M
26.07.10	BUY	ARKG	28,034	$58.25	$1.6M
26.07.09	BUY	ARKG	105,364	$64.27	$6.8M
26.03.25	SELL	ARKG	14,550	$72.70	$1.1M
26.03.13	SELL	ARKG	7,220	$71.19	$514.0K
26.03.12	SELL	ARKG	43,533	$72.34	$3.1M
26.02.27	SELL	ARKG	39,423	$81.15	$3.2M
26.01.12	SELL	ARKG	7,717	$81.66	$630.2K
26.01.06	SELL	ARKG	7,228	$81.49	$589.0K
26.01.02	SELL	ARKG	4,819	$79.67	$383.9K
25.12.31	SELL	ARKG	8,843	$79.11	$699.6K

08.19BUY

18,499

ARKGClose$60.80Est. total$1.1M

08.18BUY

26,246

ARKGClose$59.62Est. total$1.6M

08.17BUY

6,839

ARKGClose$58.63Est. total$401.0K

07.14BUY

49,003

ARKGClose$54.93Est. total$2.7M

07.13BUY

66,277

ARKGClose$56.75Est. total$3.8M

07.10BUY

28,034

ARKGClose$58.25Est. total$1.6M

07.09BUY

105,364

ARKGClose$64.27Est. total$6.8M

03.25SELL

14,550

ARKGClose$72.70Est. total$1.1M

03.13SELL

7,220

ARKGClose$71.19Est. total$514.0K

03.12SELL

43,533

ARKGClose$72.34Est. total$3.1M

02.27SELL

39,423

ARKGClose$81.15Est. total$3.2M

01.12SELL

7,717

ARKGClose$81.66Est. total$630.2K

01.06SELL

7,228

ARKGClose$81.49Est. total$589.0K

01.02SELL

4,819

ARKGClose$79.67Est. total$383.9K

12.31SELL

8,843

ARKGClose$79.11Est. total$699.6K

1 / 5

Prices estimated from market closing prices on trade dates. Actual execution prices may differ. This is not investment advice.

Stock Timeline

Institutional Holders

2 Holding · 0 Sold · Q4 2025

Based on ARK ETF real-time + 13F quarterly filings

Cathie WoodARK Invest

LIVE

530,317

Portfolio Weight

0.23%

in ETF 1.73%

Est. Value

$29M

30D Net

+$18M

Ray DalioBridgewater Associates

Increased

67,706

Portfolio Weight

0.02%

Est. Value

$5M

vs Prev Quarter

+55% (44K→68K)

13F data may be delayed up to 90 days.

Market Context

Analyst Consensus

※ Analyst opinions are for reference only and do not constitute investment advice. Each securities firm may have different opinions.

Overall Opinion

Buy

Strong Buy

Buy

Hold

Analyst Targets

avg.

$88.00

vs Current ▲ +47.3% upside

Current$59.74

Low ~ High$60.00 ~ $115.00

Firm

Position

Price Target

Upside / Downside

Close Price

Action

Date

BMO Capital

Market Perform

$60.00

+0.44%

—

Upgrade

2026-08-19

JP Morgan

Overweight

$76.00

+27.22%

—

Maintain

2026-08-03

Wells Fargo

Overweight

$95.00

+59.02%

—

Maintain

2026-07-30

HC Wainwright & Co.

Buy

$115.00

+92.50%

—

Maintain

2026-07-30

Guggenheim

Buy

$89.00

+48.98%

—

Maintain

2026-07-21

1 / 4

Avg Target

$88.00

vs Current ▲ +47.3% upside

Buy

24 analysts

Strong Buy 9Buy 10Hold 5

Low $60.00

Current $59.74

High $115.00

Firm	Position	Target	Upside	Close	Action	Date
BMO Capital	Market Perform	$60.00	+0.44%	—	Upgrade	26.08.19
JP Morgan	Overweight	$76.00	+27.22%	—	Maintain	26.08.03
Wells Fargo	Overweight	$95.00	+59.02%	—	Maintain	26.07.30
HC Wainwright & Co.	Buy	$115.00	+92.50%	—	Maintain	26.07.30
Guggenheim	Buy	$89.00	+48.98%	—	Maintain	26.07.21

1 / 4

Price Information

Previous Close$58.76

Open$59.64

Day Range$59.38 - $60.91

52-Week Range$41.71 - $86.74

1-Year Change42.85%

Trading Volume

Volume2,723,906

Avg Volume (3mo)2,914,580

Valuation

Market Cap9.9B

Book Value$2.65

Shares Outstanding166,184,322

Financials

Revenue (TTM)874.1M

Net Income-565,174,016

EPS$-3.48

EBITDA-579,484,992

Profitability

P/E Ratio-

P/B Ratio22.50

Return on Equity (ROE)-105.50%

Return on Assets (ROA)-12.42%

Profit Margin-64.66%

EV/EBITDA-17.28

Beta0.40

Dividend

Dividend Rate-

Dividend Yield-

Technical

RSI(14)66.99

Company Overview

Ionis Pharmaceuticals is a commercial-stage biotechnology company specializing in RNA-targeted medicines. Their main products include treatments for rare genetic neurological diseases like spinal muscular atrophy (SMA), hereditary transthyretin-mediated amyloidosis (ATTRv-PN), and ALS, as well as conditions like familial chylomicronemia syndrome (FCS). Ionis holds a significant position in the market for developing innovative therapies for these unmet medical needs.

P/B

22.50

High valuation

ROE

-105.5%

Persistent loss

Beta

0.40

Low volatility

RSI(14)

67.0

Neutral zone

AI-generated summary. Not investment advice.

Ionis Pharmaceuticals, Inc.

Analyst Consensus

Price Information

Trading Volume

Valuation

Financials

Profitability

Dividend

Technical

Related ARK stocks